Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 May 30;10(11):2436.
doi: 10.3390/jcm10112436.

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)

Prem Patel  1 , Veeral Sheth  2
Affiliations
Review

New and Innovative Treatments for Neovascular Age-Related Macular Degeneration (nAMD)

Prem Patel et al. J Clin Med. .

Abstract

Age-related macular degeneration (AMD) is one of the most common causes of vision loss. Advanced forms of AMD are seen in primarily two types-neovascular AMD (nAMD) with the presence of choroid neovascularization and non-neovascular AMD (nnAMD) with geographic atrophy. Neovascular AMD is characterized by choroidal neovascularization (CNV), which leads to a cascade of complications, including exudation, leakage, and ultimately fibrosis with photoreceptor loss. Inhibition of VEGF represents the current standard of care. However, there is a tremendous gap between the outcomes in randomized clinical trials and real-world settings. New agents for nAMD might offer the potential to improve treatment outcomes and reduce treatment of frequent intravitreal injections. We summarize all the newer molecules, their pivotal clinical trial results, and their unique mechanisms of action; these include longer-acting agents, combination strategies, sustained release, and genetic therapies.

Keywords: Vascular Endothelial Growth Factor (VEGF); emerging treatment; neovascular age-related macular degeneration (nAMD).

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Mechanisms of action of Neovascular age-related macular degeneration therapies in development.
See this image and copyright information in PMC

References

    1. Klein R. Prevalence of age-related macular degeneration in the US population. Arch. Ophthal. 2011;129:75. doi: 10.1001/archophthalmol.2010.318. - DOI - PubMed
    1. Klein B.E.K. Forecasting age-related macular degeneration through 2050. JAMA. 2009;301:2152–2153. doi: 10.1001/jama.2009.729. - DOI - PubMed
    1. Bourne R.R.A., Jonas J.B., Bron A.M., Cicinelli M.V., Das A., Flaxman S.R., Friedman D.S., Keeffe J.E., Kempen J.H., Leasher J., et al. Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe in 2015: Magnitude, temporal trends and projections. Br. J. Ophthalmol. 2018;102:575–585. doi: 10.1136/bjophthalmol-2017-311258. - DOI - PMC - PubMed
    1. Wong W.L., Su X., Li X., Cheung C.M., Klein R., Cheng C.Y., Wong T.Y. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis. Lancet Glob. Health. 2014;2:e106–e116. doi: 10.1016/S2214-109X(13)70145-1. - DOI - PubMed
    1. Ferris F.L., Wilkinson C.P., Bird A., Chakravarthy U., Chew E., Csaky K., Sadda S.R. Clinical Classification of Age-related Macular Degeneration. Ophthalmology. 2013;120:844–851. doi: 10.1016/j.ophtha.2012.10.036. - DOI - PMC - PubMed

LinkOut - more resources